Procainamide-induced	procainamide-induced	O	O	O	O
polymorphous	polymorphous	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Seven	seven	O	O	O	O
cases	cases	O	O	O	O
of	of	O	O	O	O
procainamide-induced	procainamide-induced	O	O	O	O
polymorphous	polymorphous	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
are	are	O	O	O	O
presented	presented	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
four	four	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
polymorphous	polymorphous	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
appeared	appeared	O	O	O	O
after	after	O	O	O	O
intravenous	intravenous	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
200	200	O	O	O	O
to	to	O	O	O	O
400	400	O	O	O	O
mg	mg	O	O	OTHERS	I
of	of	O	O	O	O
procainamide	procainamide	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
the	the	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
sustained	sustained	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
remaining	remaining	O	O	O	O
three	three	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
procainamide	procainamide	CHEMICALS	O	OTHERS	I
was	was	O	O	O	O
administered	administered	O	O	O	O
orally	orally	O	O	O	O
for	for	O	O	O	O
treatment	treatment	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	O	O	O
premature	premature	O	O	OTHERS	I
ventricular	ventricular	O	O	OTHERS	I
contractions	contractions	O	O	OTHERS	I
or	or	O	O	O	O
atrial	atrial	O	DISEASE	OTHERS	I
flutter	flutter	O	DISEASE	OTHERS	I
.	.	O	O	O	O

These	these	O	O	O	O
patients	patients	O	O	O	O
had	had	O	O	O	O
Q-T	q-t	O	O	O	O
prolongation	prolongation	O	O	O	O
and	and	O	O	O	O
recurrent	recurrent	O	O	O	O
syncope	syncope	O	DISEASE	OTHERS	I
due	due	O	O	O	O
to	to	O	O	O	O
polymorphous	polymorphous	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
four	four	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
arrhythmia	arrhythmia	O	DISEASE	OTHERS	I
was	was	O	O	O	O
rapidly	rapidly	O	O	O	O
diagnosed	diagnosed	O	O	O	O
and	and	O	O	O	O
treated	treated	O	O	O	O
with	with	O	O	O	O
disappearance	disappearance	O	O	O	O
of	of	O	O	O	O
further	further	O	O	O	O
episodes	episodes	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
arrhythmia	arrhythmia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
two	two	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
arrhythmia	arrhythmia	O	DISEASE	OTHERS	I
degenerated	degenerated	O	O	O	O
into	into	O	O	O	O
irreversible	irreversible	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
fibrillation	fibrillation	O	DISEASE	OTHERS	I
and	and	O	O	O	O
both	both	O	O	O	O
patients	patients	O	O	O	O
died	died	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
seventh	seventh	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
a	a	O	O	O	O
permanent	permanent	O	O	O	O
ventricular	ventricular	O	O	O	O
pacemaker	pacemaker	O	O	O	O
was	was	O	O	O	O
inserted	inserted	O	O	O	O
and	and	O	O	O	O
,	,	O	O	O	O
despite	despite	O	O	O	O
continuation	continuation	O	O	O	O
of	of	O	O	O	O
procainamide	procainamide	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
,	,	O	O	O	O
polymorphous	polymorphous	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
did	did	O	O	O	O
not	not	O	O	O	O
reoccur	reoccur	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
seven	seven	O	O	O	O
cases	cases	O	O	O	O
demonstrate	demonstrate	O	O	O	O
that	that	O	O	O	O
procainamide	procainamide	CHEMICALS	O	OTHERS	I
can	can	O	O	O	O
produce	produce	O	O	O	O
an	an	O	O	O	O
acquired	acquired	O	O	O	O
prolonged	prolonged	O	O	O	O
Q-T	q-t	O	O	O	O
syndrome	syndrome	O	O	O	O
with	with	O	O	O	O
polymorphous	polymorphous	O	O	O	O
ventricular	ventricular	O	DISEASE	OTHERS	I
tachycardia	tachycardia	O	DISEASE	OTHERS	I
.	.	O	O	O	O

